Cancer discoveryPub Date : 2024-11-21DOI: 10.1158/2159-8290.cd-23-1422
Sapir Cohen Shvefel, Joy A. Pai, Yingying Cao, Lipika R. Pal, Osnat Bartok, Ronen Levy, Marie J. Zemanek, Chen Weller, Ella Herzog, Winnie Yao, Kamir J. Hiam-Galvez, Kuoyuan Cheng, Yajie Yin, Peter P. Du, Colin J. Raposo, Nofar Gumpert, Michele Welti, Julia M. Martínez Gómez, Federica Sella, Elizabeta Yakubovich, Irit Orr, Shifra Ben-Dor, Roni Oren, Liat Fellus-Alyagor, Ofra Golani, Ori Jacob. Brenner, Tomer M. Salame, Mirie Zerbib, Inna Goliand, Dean Ranmar, Ilya Savchenko, Nadav Ketrarou, Alejandro A. Schaffer, Rony Dahan, Mitchell P. Levesque, Eytan Ruppin, Ansuman T. Satpathy, Yardena Samuels
{"title":"Temporal genomic analysis of homogeneous tumor models reveals key regulators of immune evasion in melanoma","authors":"Sapir Cohen Shvefel, Joy A. Pai, Yingying Cao, Lipika R. Pal, Osnat Bartok, Ronen Levy, Marie J. Zemanek, Chen Weller, Ella Herzog, Winnie Yao, Kamir J. Hiam-Galvez, Kuoyuan Cheng, Yajie Yin, Peter P. Du, Colin J. Raposo, Nofar Gumpert, Michele Welti, Julia M. Martínez Gómez, Federica Sella, Elizabeta Yakubovich, Irit Orr, Shifra Ben-Dor, Roni Oren, Liat Fellus-Alyagor, Ofra Golani, Ori Jacob. Brenner, Tomer M. Salame, Mirie Zerbib, Inna Goliand, Dean Ranmar, Ilya Savchenko, Nadav Ketrarou, Alejandro A. Schaffer, Rony Dahan, Mitchell P. Levesque, Eytan Ruppin, Ansuman T. Satpathy, Yardena Samuels","doi":"10.1158/2159-8290.cd-23-1422","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-23-1422","url":null,"abstract":"Low intra-tumor heterogeneity (ITH) correlates with increased patient survival and immunotherapy response. However, even highly homogeneous tumors are variably aggressive, and the immunological factors impacting aggressiveness remain understudied. Here, we analyzed the mechanisms underlying immune escape in murine tumors with low ITH. We used immunophenotyping and single-cell RNA sequencing to compare the temporal growth of in-vivo transplanted, genetically similar rejected vs. non-rejected single-cell clones. Non-rejected clones showed high infiltration of tumor-associated macrophages (TAMs), lower T-cell infiltration, and increased T-cell exhaustion compared to rejected clones. Comparative analysis of rejection-associated gene expression programs, combined with in-vivo CRISPR knockout screens of candidate regulators, identified Mif (macrophage migration inhibitory factor) as a major contributor to immune rejection. Mif knockout resulted in smaller tumors and reduced TAM infiltration. These results were validated in melanoma patient data. Overall, our homogeneous tumor system can uncover factors regulating growth variability and identifies Mif as critical in aggressive melanoma.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"6 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-19DOI: 10.1158/2159-8290.CD-24-1215
Katherine E Lindblad, Romain Donne, Ian Liebling, Marina Barcena-Varela, Anthony Lozano, Marina Ruiz de Galarreta, Maxime Dhainaut, Nesteene J Param, Bruno Giotti, Sarah Cappuyns, Takahiro Kodama, Yulei Wang, Alice O Kamphorst, Alexander M Tsankov, Amaia Lujambio
{"title":"NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma.","authors":"Katherine E Lindblad, Romain Donne, Ian Liebling, Marina Barcena-Varela, Anthony Lozano, Marina Ruiz de Galarreta, Maxime Dhainaut, Nesteene J Param, Bruno Giotti, Sarah Cappuyns, Takahiro Kodama, Yulei Wang, Alice O Kamphorst, Alexander M Tsankov, Amaia Lujambio","doi":"10.1158/2159-8290.CD-24-1215","DOIUrl":"10.1158/2159-8290.CD-24-1215","url":null,"abstract":"<p><p>Hepatocellular carcinoma presents strong sexual dimorphism, being 2-3 times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic anti-tumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced anti-tumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in DC-mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC-CD8+ T cell axis with CD40 agonism to improve outcomes.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":""},"PeriodicalIF":29.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-19DOI: 10.1158/2159-8290.CD-24-0928
Shane T Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry Dillon, Suzanne E Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu, Donald P McDonnell, Ann Marie Pendergast, Kris C Wood
{"title":"PKN2 is a dependency of the mesenchymal-like cancer cell state.","authors":"Shane T Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry Dillon, Suzanne E Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu, Donald P McDonnell, Ann Marie Pendergast, Kris C Wood","doi":"10.1158/2159-8290.CD-24-0928","DOIUrl":"10.1158/2159-8290.CD-24-0928","url":null,"abstract":"<p><p>Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. Here, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ~800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Co-essentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2-SAV1-TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF oncogenes suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":""},"PeriodicalIF":29.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-14DOI: 10.1158/2159-8290.cd-24-0435
Yi Bao, Gabriel Cruz, Yuping Zhang, Yuanyuan Qiao, Rahul Mannan, Jing Hu, Fan Yang, Mahnoor Gondal, Miriam Shahine, Sarah Kang, Somnath Mahapatra, Alec Chu, Jae Eun Choi, Jiali Yu, Heng Lin, Stephanie J. Miner, Dan R. Robinson, Yi-Mi Wu, Yang Zheng, Xuhong Cao, Fengyun Su, Rui Wang, Noshad Hosseini, Marcin Cieslik, Ilona Kryczek, Ulka Vaishampayan, Weiping Zou, Arul M. Chinnaiyan
{"title":"The UBA1-STUB1 axis mediates cancer immune escape and resistance to checkpoint blockade","authors":"Yi Bao, Gabriel Cruz, Yuping Zhang, Yuanyuan Qiao, Rahul Mannan, Jing Hu, Fan Yang, Mahnoor Gondal, Miriam Shahine, Sarah Kang, Somnath Mahapatra, Alec Chu, Jae Eun Choi, Jiali Yu, Heng Lin, Stephanie J. Miner, Dan R. Robinson, Yi-Mi Wu, Yang Zheng, Xuhong Cao, Fengyun Su, Rui Wang, Noshad Hosseini, Marcin Cieslik, Ilona Kryczek, Ulka Vaishampayan, Weiping Zou, Arul M. Chinnaiyan","doi":"10.1158/2159-8290.cd-24-0435","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-24-0435","url":null,"abstract":"How cancer cells escape immune surveillance and resist immune checkpoint blockade (ICB) remains to be fully elucidated. By screening candidate genes frequently gained in cancer, we identified expression of ubiquitin-like modifier activating enzyme 1 (UBA1) as being the most negatively correlated with signatures related to effector CD8+ T-cells. High UBA1 expression was strongly predictive of treatment resistance and poor survival in ICB cohorts. Functional studies revealed that UBA1 mediated immune escape to promote tumor growth. Immune profiling further showed that Uba1 overexpression or depletion markedly decreased or increased functional intratumoral CD8+ T-cells, respectively. Importantly, a selective UBA1 inhibitor, TAK-243, significantly synergized with ICB in multiple syngeneic models. Mechanistically, depletion or inactivation of the UBA1-STUB1 axis stabilized a key interferon pathway component (JAK1), enhanced IFN-signaling, and elevated key immune modulators, including CXCL9, CXCL10, and MHC class I. Our study warrants clinical evaluation of the combination of UBA1 inhibitors and ICB.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"31 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-11DOI: 10.1158/2159-8290.cd-24-0263
Sara Canato, Rahul Sarate, Sofia Carvalho-Marques, Raquel Maia Soares, Yura Song, Sara Monteiro-Ferreira, Pauline Vieugué, Mélanie Liagre, Giancarlo Grossi, Erik Cardoso, Christine Dubois, Edward M. Conway, Silvia Schenone, Adriana Sanchez-Danes, Cedric Blanpain
{"title":"Survivin promotes stem cell competence for skin cancer initiation","authors":"Sara Canato, Rahul Sarate, Sofia Carvalho-Marques, Raquel Maia Soares, Yura Song, Sara Monteiro-Ferreira, Pauline Vieugué, Mélanie Liagre, Giancarlo Grossi, Erik Cardoso, Christine Dubois, Edward M. Conway, Silvia Schenone, Adriana Sanchez-Danes, Cedric Blanpain","doi":"10.1158/2159-8290.cd-24-0263","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-24-0263","url":null,"abstract":"Stem cells (SCs) and not progenitors (Ps) act as cells of origin of Basal Cell Carcinoma (BCC). The mechanisms promoting BCC formation in SCs or restricting tumour development in Ps are currently unknown. In this study, we transcriptionally profiled SCs and Ps and found that Survivin, a pleiotropic factor that promotes cell division and inhibits apoptosis was preferentially expressed in SCs. Using genetic gain and loss of function mouse models, we showed that Survivin deletion in oncogene-expressing SCs prevents BCC formation. Survivin overexpression renders Ps competent to BCC formation by promoting cell survival and division while preventing apoptosis and differentiation. We identified SGK1, as a key downstream factor of Survivin, and its inhibition prevents BCC formation. This study uncovers the role and mechanisms by which Survivin regulates the competence of SCs to initiate BCC formation promoting the survival of oncogene-expressing SCs and self-renewing division while restricting differentiation and apoptosis.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"245 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-08DOI: 10.1158/2159-8290.cd-24-0718
Tala FNU, Peiguo Shi, Wanwei Zhang, Sanny S.W. Chung, Christopher B. Damoci, Yinshan Fang, Qi-Yue Chen, Anjali Saqi, Yuefeng Huang, Xuebing Wu, Chao Lu, Dian Yang, Timothy C. Wang, Jianwen Que
{"title":"Sympathetic Neurons Promote Small Cell Lung Cancer Through the Beta-2 Adrenergic Receptor","authors":"Tala FNU, Peiguo Shi, Wanwei Zhang, Sanny S.W. Chung, Christopher B. Damoci, Yinshan Fang, Qi-Yue Chen, Anjali Saqi, Yuefeng Huang, Xuebing Wu, Chao Lu, Dian Yang, Timothy C. Wang, Jianwen Que","doi":"10.1158/2159-8290.cd-24-0718","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-24-0718","url":null,"abstract":"The vagal nerve is linked to tumorigenesis in multiple tissues including small cell lung cancer (SCLC). However, the role of sympathetic neuron in SCLC development remains unknown. Here, we observed a significant reduction in tumor growth following chemical denervation of local sympathetic nerves in a mouse model of SCLC. Further study identified that β2-adrenergic receptor (ADRB2) on cancer cells mediated the crosstalk with nerve fibers. Genetic deletion or pharmacological inhibition of ADRB2 led to reduced tumor growth and improved survival. Moreover, blocking ADRB2 also reduced the growth of human SCLC organoids and xenografts. Further studies revealed that ADRB2 promoted cancer cell expansion through activating Protein Kinase A (PKA) signaling. Consistently, inhibition of PKA also reduced the growth of SCLC cells. These findings offer the initial insight into the role played by sympathetic neurons in the development of SCLC and may open a new therapeutic avenue to treat this deadly malignancy.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"70 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-01DOI: 10.1158/2159-8290.CD-24-0838
Chaoqi Zhang, Peng Wu, Dongyu Li, Xuanyu Gu, Chuqi Lin, Junhan Zhou, Dexin Shang, Jingjing Liu, Ruijie Ma, Bohui Zhao, Nan Sun, Jie He
{"title":"A Call for Innovative Translational and Clinical Research to Address China's Unique Cancer Landscape.","authors":"Chaoqi Zhang, Peng Wu, Dongyu Li, Xuanyu Gu, Chuqi Lin, Junhan Zhou, Dexin Shang, Jingjing Liu, Ruijie Ma, Bohui Zhao, Nan Sun, Jie He","doi":"10.1158/2159-8290.CD-24-0838","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-24-0838","url":null,"abstract":"<p><p>The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 11","pages":"2028-2032"},"PeriodicalIF":29.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-01DOI: 10.1158/2159-8290.CD-24-0421
Haniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, Minh Truong Do, Xin Hu, Frank R Rojas Alvarez, Maria E Salvatierra, Heladio P Ibarguen, Richard Lee, Rashi Raghulan, Harshit Shah, Mariela A Moreno Ayala, Kevin Chen, Nataliya Tovbis Shifrin, Shuhong Wu, Luisa M Solis Soto, Marcelo V Negrao, Don L Gibbons, David S Hong, Jack A Roth, John V Heymach, Jianjun Zhang, Jingjing Jiang, Mallika Singh, Jacqueline A M Smith, Elsa Quintana, Ferdinandos Skoulidis
{"title":"Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer.","authors":"Haniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, Minh Truong Do, Xin Hu, Frank R Rojas Alvarez, Maria E Salvatierra, Heladio P Ibarguen, Richard Lee, Rashi Raghulan, Harshit Shah, Mariela A Moreno Ayala, Kevin Chen, Nataliya Tovbis Shifrin, Shuhong Wu, Luisa M Solis Soto, Marcelo V Negrao, Don L Gibbons, David S Hong, Jack A Roth, John V Heymach, Jianjun Zhang, Jingjing Jiang, Mallika Singh, Jacqueline A M Smith, Elsa Quintana, Ferdinandos Skoulidis","doi":"10.1158/2159-8290.CD-24-0421","DOIUrl":"10.1158/2159-8290.CD-24-0421","url":null,"abstract":"<p><p>Resistance to inactive state-selective RASG12C inhibitors frequently entails accumulation of RASGTP, rendering effective inhibition of active RAS potentially desirable. Here, we evaluated the antitumor activity of the RAS(ON) multiselective tricomplex inhibitor RMC-7977 and dissected mechanisms of response and tolerance in KRASG12C-mutant non-small cell lung cancer (NSCLC). Broad-spectrum reversible RASGTP inhibition with or without concurrent covalent targeting of active RASG12C yielded superior and differentiated antitumor activity across diverse comutational KRASG12C-mutant NSCLC mouse models of primary or acquired RASG12C(ON) or RASG12C(OFF) inhibitor resistance. Interrogation of time-resolved single-cell transcriptional responses established an in vivo atlas of multimodal acute and chronic RAS pathway inhibition in the NSCLC ecosystem and uncovered a regenerative mucinous transcriptional program that supports long-term tumor cell persistence. In patients with advanced KRASG12C-mutant NSCLC, the presence of mucinous histologic features portended poor response to sotorasib or adagrasib. Our results have potential implications for personalized medicine and the development of rational RAS inhibitor-anchored therapeutic strategies. Significance: Our work reveals robust and durable antitumor activity of the preclinical RAS(ON) multiselective inhibitor RMC-7977 against difficult-to-treat subsets of KRASG12C-mutant NSCLC with primary or acquired RASG12C inhibitor resistance and identifies a conserved mucinous transcriptional state that supports RAS inhibitor tolerance. See related commentary by Marasco and Misale, p. 2018.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"2183-2208"},"PeriodicalIF":29.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Building an Organ-Wide Macroscopic View of Cancer Hallmarks.","authors":"Suling Liu, Yuan Wang, Jiawen Feng, Zhihua Liu, Shengtao Zhou","doi":"10.1158/2159-8290.CD-24-0833","DOIUrl":"10.1158/2159-8290.CD-24-0833","url":null,"abstract":"<p><p>Despite an increasingly detailed understanding of cancer hallmarks at molecular or atomic resolution, most studies, however, fall short of investigating the systemic interactions of cancer with the human body. We propose to investigate the hallmarks of cancer from an organ-wide macroscopic view, discuss the challenges in preclinical and clinical research to study the cross-organ regulation of cancer together with potential directions to overcome these challenges, and foresee how this holistic view may be translated into more effective therapies.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 11","pages":"2041-2046"},"PeriodicalIF":29.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer discoveryPub Date : 2024-11-01DOI: 10.1158/2159-8290.CD-24-0519
Peter J Mazzone, Peter B Bach, Jacob Carey, Caitlin A Schonewolf, Katalin Bognar, Manmeet S Ahluwalia, Marcia Cruz-Correa, David Gierada, Sonali Kotagiri, Kathryn Lloyd, Fabien Maldonado, Jesse D Ortendahl, Lecia V Sequist, Gerard A Silvestri, Nichole Tanner, Jeffrey C Thompson, Anil Vachani, Kwok-Kin Wong, Ali H Zaidi, Joseph Catallini, Ariel Gershman, Keith Lumbard, Laurel K Millberg, Jeff Nawrocki, Carter Portwood, Aakanksha Rangnekar, Carolina Campos Sheridan, Niti Trivedi, Tony Wu, Yuhua Zong, Lindsey Cotton, Allison Ryan, Christopher Cisar, Alessandro Leal, Nicholas Dracopoli, Robert B Scharpf, Victor E Velculescu, Luke R G Pike
{"title":"Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.","authors":"Peter J Mazzone, Peter B Bach, Jacob Carey, Caitlin A Schonewolf, Katalin Bognar, Manmeet S Ahluwalia, Marcia Cruz-Correa, David Gierada, Sonali Kotagiri, Kathryn Lloyd, Fabien Maldonado, Jesse D Ortendahl, Lecia V Sequist, Gerard A Silvestri, Nichole Tanner, Jeffrey C Thompson, Anil Vachani, Kwok-Kin Wong, Ali H Zaidi, Joseph Catallini, Ariel Gershman, Keith Lumbard, Laurel K Millberg, Jeff Nawrocki, Carter Portwood, Aakanksha Rangnekar, Carolina Campos Sheridan, Niti Trivedi, Tony Wu, Yuhua Zong, Lindsey Cotton, Allison Ryan, Christopher Cisar, Alessandro Leal, Nicholas Dracopoli, Robert B Scharpf, Victor E Velculescu, Luke R G Pike","doi":"10.1158/2159-8290.CD-24-0519","DOIUrl":"10.1158/2159-8290.CD-24-0519","url":null,"abstract":"<p><p>Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when positive is followed by a low-dose computed tomography. Changes in genome-wide cell-free DNA fragmentation profiles (fragmentomes) in peripheral blood reflected genomic and chromatin characteristics of lung cancer. We applied machine learning to fragmentome features to identify individuals who were more or less likely to have lung cancer. We trained the classifier using 576 cases and controls from study samples and validated it in a held-out group of 382 cases and controls. The validation demonstrated high sensitivity for lung cancer and consistency across demographic groups and comorbid conditions. Applying test performance to the screening eligible population in a 5-year model with modest utilization assumptions suggested the potential to prevent thousands of lung cancer deaths. Significance: Lung cancer screening has poor adoption. Our study describes the development and validation of a novel blood-based lung cancer screening test utilizing a highly affordable, low-coverage genome-wide sequencing platform to analyze cell-free DNA fragmentation patterns. The test could improve lung cancer screening rates leading to substantial public health benefits. See related commentary by Haber and Skates, p. 2025.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"2224-2242"},"PeriodicalIF":29.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}